These data indicate that simultaneous inhibition of WNT5A and RhoA signaling is a more effective strategy for hindering tumor cell invasion of BRAF wild‐type and BRAFV600 mutated melanomas treated with a BRAF inhibitor than targeting either WNT5A or RhoA individually. The gene discussed is BRAF; the disease is neoplasm.